Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02355340 · ClinicalTrials.gov registry record
Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 22
- Enrollment target
NCT02355340: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT02355340 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02355340 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
This research study is evaluating bone mineral density in childhood cancer survivors who have a history of bone fracture.
Primary Outcome
DXA assessment (z-score)
Interventions
- OTHER Dual energy x-ray absorptiometry (DXA)
- OTHER Peripheral quantitative computed tomography (pQCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-05 |
| Est. Completion | 2024-06-07 |
What the finished NCT02355340 record still lists
NCT02355340 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Dual energy x-ray absorptiometry (DXA) is the first listed.
NCT02355340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02355340 about?
NCT02355340 is a clinical study titled "Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture". This research study is evaluating bone mineral density in childhood cancer survivors who have a history of bone fracture.
What is the current status of trial NCT02355340?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2015-05. Estimated completion is 2024-06-07.
What interventions are being tested in trial NCT02355340?
The interventions under investigation include: Dual energy x-ray absorptiometry (DXA) (OTHER), Peripheral quantitative computed tomography (pQCT) (OTHER).
Who is sponsoring clinical trial NCT02355340?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia